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The etiology of inflammatory bowel diseases is only partially explained by the current genetic risk map. It is hypothesized
that environmental factors modulate the epigenetic landscape and thus contribute to disease susceptibility, manifestation,
and progression. To test this, we analyzed DNAmethylation (DNAm), a fundamental mechanism of epigenetic long-term
modulation of gene expression. We report a three-layer epigenome-wide association study (EWAS) using intestinal bi-
opsies from 10 monozygotic twin pairs (n = 20 individuals) discordant for manifestation of ulcerative colitis (UC). Genome-
wide expression scans were generated using Affymetrix UG 133 Plus 2.0 arrays (layer 1). Genome-wide DNAm scans were
carried out using Illumina 27k Infinium Bead Arrays to identify methylation variable positions (MVPs, layer 2), and
MeDIP-chip on Nimblegen custom 385k Tiling Arrays to identify differentially methylated regions (DMRs, layer 3).
Identified MVPs and DMRs were validated in two independent patient populations by quantitative real-time PCR and
bisulfite-pyrosequencing (n = 185). The EWAS identified 61 disease-associated loci harboring differential DNAm in cis of
a differentially expressed transcript. All constitute novel candidate risk loci for UC not previously identified by GWAS.
Among them are several that have been functionally implicated in inflammatory processes, e.g., complement factor CFI,
the serine protease inhibitor SPINK4, and the adhesion molecule THY1 (also known as CD90). Our study design excludes
nondisease inflammation as a cause of the identified changes in DNAm. This study represents the first replicated EWAS of
UC integrated with transcriptional signatures in the affected tissue and demonstrates the power of EWAS to uncover
unexplained disease risk and molecular events of disease manifestation.
[Supplemental material is available for this article.]
Ulcerative colitis (UC) represents onemajor subphenotype (OMIM
191390) of human inflammatory bowel disease (IBD, OMIM
266600) and is characterized by chronic inflammation of the in-
testinal mucosa, exhibiting a continuous pattern in the affected
tissue. In the past decades, the disease displayed a remarkably steep
rise in incidence, which cannot be explained by genetic variants
exclusively. Current estimations attribute ;16% of the disease
heritability to identified genetic variants (Anderson et al. 2011),
while environmental changes interacting with genetic pre-
disposition (Hampe et al. 1999; Stoll et al. 2004; Franke et al. 2008,
2010) are discussed as major determinants for disease manifesta-
tion (Rosenstiel et al. 2009). This is in concordance with observa-
tions for other complex diseases (Manolio et al. 2009). However,
neither the relapsing/remitting nature of the inflammatory pro-
cess nor the delayed onset after several decades of health is un-
derstood. To address this gap, several studies have focused on the
functional genomics of UC in order to obtain a high-resolution
transcriptional picture of disease processes in the inflamedmucosa
(Dieckgraefe et al. 2000; Lawrance et al. 2001; Costello et al. 2005).
Beyond germline DNA variants, epigenetic variants, e.g., DNA
methylation (DNAm) and histone modifications, could modulate
disease-relevant gene function (Petronis 2010). Epigenetic patterns
are highly tissue-specific (Rakyan et al. 2008) and can be influenced
by environmental factors (Mann et al. 2004; Heijmans et al. 2008).
Recent technological advances have assessed the degree of methyla-
tionof specificCpG sites as regulators of disease-associated transcripts
(van Overveld et al. 2003; Petronis 2010). Consequently, epigenetic
modifications represent promising candidates for elucidating pro-
cesses of disease manifestation beyond the identified risk loci. A
genome-wide study assessing the role of DNAm in the primary dis-
eased tissue of a chronic inflammatory disorder, such as UC, could
therefore lead to signatures that capture the environmental in-
fluence on patients. A particularly powerful approach for addressing
epigeneticmechanisms is the study of discordantmonozygotic (MZ)
twins (Bell and Spector 2011). Except for highly penetrant Mende-
lian disorders, MZ twins exhibit a broad range (25%–95%) of disease
discordance for most complex diseases that cannot be explained by
classical genetics (Nance 1977). A recent report showed a discor-
dance rate of 84% in MZ twins for UC (Spehlmann et al. 2008).
While, historically, twin-based studies have been employed for the
identification of disease genes, recent interest inMZ twin studies has
moved to mapping epigenetic changes in identical genomes that
have precipitated into different phenotypes (Fraga et al. 2005;
Kaminsky et al. 2009; Javierre et al. 2010; Rakyan et al. 2011a).
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Starting with a collection of mucosal biopsies from 20 MZ
twins, discordant for UC, we aimed to generate a genome-wide
functional epigeneticmap independent of the genetic background
by combining three essential layers of information: (1) Genome-
wide mRNA expression profiling; (2) genome-wide quantification
of methylation variable positions (MVPs) representing individual
methylation events within the proximal promoter regions of
transcription start sites; and (3) genome-wide assessment of dif-
ferentially methylated regions (DMRs) representing group effects
of linked MVPs. Combining these three layers and validation of
selected findings in an independent cohort of unrelated in-
dividuals illustrates the potential impact of functional epigenetics
on disease mechanisms in UC.
Results
Three-layer genome-wide scans for differential gene
expression, MVPs, and DMRs in twins, discordant for UC
The transcriptome analysis (layer #1) of the mucosa of 20 MZ
twins, discordant for UC, identified 18,097 out of 54,675 tran-
scripts analyzed as expressed. Of these, 361 were significantly
differentially expressed (Benjamini-Hochberg-corrected P-value #
0.05; FDR [false discovery rate] # 5%) and 356 were in close
proximity (50 kb) of at least one MVP or DMR. The MVP analysis
(layer #2) involved interrogation of 27,578 CpG sites, of which
23,085were informative, resulting in the identification of 703MVPs
between healthy and diseased individuals (Benjamini-Hochberg-
corrected P-value# 0.05). The DMR analysis (layer #3) involved the
examination of 392,750 positions, of which 389,359 were in-
formative in the mucosal tissue sample, resulting in the identifi-
cation of 345 DMRs between healthy and diseased individuals
(Benjamini-Hochberg-corrected P-value # 0.05).
A genome-wide functional epigenetic map for UC
Integration of the three layers illustrates that epigenetic differences
as well as their potential transcriptional consequences can be
monitored in complex primary tissue on a genome-wide scale (Fig.
1; high resolution maps of individual chromosomes, see Supple-
mental Fig. S1A–X). The observed DNAm follows the expected
bimodal distribution (Supplemental Fig. S2). Hypomethylation is
prominent in promoter regions (Supplemental Fig. S3A), while
hypermethylation ismore frequent in gene-introns (Supplemental
Fig. S3B). Similar patterns of variability were observed for all three
layers, as documented by the intra-class correlations (Supple-
mental Fig. S4). The principal component analysis identified dis-
ease as the strongest component. Notably, mRNA and DNAm did
not contribute equally to the separation between healthy and
diseased individuals (Supplemental Fig. S5). Collectively, the three-
layer analysis identified 61 disease-associated genes that were de-
fined by differential expression and at least one MVP or DMR
within a cis-interaction window of 50 kb (Supplemental Table S1)
from the transcription start site. Disease-associated transcripts
were defined by their significantly differential mRNA expression
when comparing healthy individuals to UC patients (Benjamini-
Hochberg-corrected P-value # 0.05; false discovery rate # 5%).
Unsupervised clustering of these 61 mRNA/DNAm pairs revealed
patient similarities of mRNA and DNAm levels (Supplemental Fig.
S6). Correlation analysis of quantitative expression values and
MVP or DMR data revealed a correlation in selected candidate
transcripts (median Spearman-r r = 0.58), a correlation in identified
candidate loci (r = 0.49), no correlation in the group of disease-
associated transcripts (r = 0.15), andno correlationwhen analyzing
all transcripts (r = 0.16). The correlation within the selected can-
didates was significantly different from all other gene-sets (Sup-
plemental Fig. S7). A large number of differentially expressed
transcripts (independent of MVPs andDMRs) were associatedwith
inflammation, immune response, and other disease-relevant pro-
cesses when performing a gene ontology (GO) analysis. Similarly,
differentially expressed transcripts in close proximity to MVPs
and/or DMRs were also found to be associated with inflammation
and immune response (Supplemental Fig. S8). The variant patterns
observed in the validation panel displayed high robustness, as
documented by the frequencies of their respective occurrences: A
random individual from the validation panel has a median chance
of over 80% of exhibiting the variant pattern described for the
10 candidate loci (Supplemental Fig. S9).
A direct comparison of the results for mRNA, MVP, and DMR
levels to 47 previously published UC-associated loci (Anderson
et al. 2011) revealed that none of those loci exhibited significant
alterations for any of the three layers investigated (Supplemental
Table S2).
Figure 1. (A) Genome-wide profiles of DNAm and gene expression. The
x-axis represents the genomic location with chromosomes represented as
rows. The y-axis represents the significance of the differences between UC
patients and healthy individuals and is displayed as –log(p) for the mRNA
and as log(p) for the epigenetic modifications. Effect size (induction/fold
change) is encoded by colors. Methylation: (black) up-regulated, (blue)
not regulated, (purple) down-regulated; mRNA-expression: (red) up-
regulated, (yellow) no regulation, (green) down-regulated. (B) Higher
resolution map for selected candidate locus HKDC1 (display and color
coding according to Fig. 1A; the dotted line indicates the significance
threshold). A higher resolution of this map is provided in Supplemental
Figure S1A–X.
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Validation of selected candidate transcripts under potential
epigenetic control
Of the 61 disease- and MVP/DMR-associated transcripts, 10
candidates with the closest proximity between MVP/DMRs and
transcript location were subjected to further validation and
replication in a larger collection of primary tissue from the in-
testinal mucosa (Table 1, validation panel I and II). This was
performed by pyrosequencing (bisulfite-modified DNA, n = 50
individuals) for methylation analysis and TaqMan-based real-
time PCR (n = 135 individuals) for differential mRNA expression.
Significance criteria were defined in concordance with the initial
scan (Benjamini-Hochberg-corrected P-value # 0.05) (details on
the panel of patients and controls are listed in Table 1; for de-
tailed description of the methods, see Supplemental Material).
The results are summarized in Table 2. We selected distinct pat-
terns of differential DNAm/expression pairs as paradigms for
different scenarios of epigenetic modulation while focusing
on the commonly accepted pattern of hypermethylation with
transcriptional repression and hypomethylation to be associated
with increased mRNA expression. (1) Pairs with negative corre-
lation of DNAm and mRNA expression, represented by 40 MVPs
and five transcripts: increased DNAm accompanied by decreased
mRNA expression (MT1H) and decreased DNAm with increased
mRNA expression (CFI, HKDC1, SPINK4, THY1); (2) pairs with
positive correlation of DNAmandmRNA expression, represented
by 21MVPs and three transcripts: increased DNAm accompanied
by increased mRNA expression (TK1), and decreased DNAm
with decreased mRNA expression (FLNA, PTN). Control loci were
chosen to replicate MVPs/DMRs without a cis-modulation of
mRNA expression (SLC7A7, 4 MVPs) or differential mRNA
expression without multiple MVPs or DMRs (IGHG1, 1 MVP). We
found MVPs and DMRs to be associated with alterations in ex-
pression levels occurring both at the start of a CpG island (HKDC1,
TK1) as well as at the end of a CpG island (all other candidates),
generally referred to as CpG island shores (Doi et al. 2009; Irizarry
et al. 2009). Results for one selected example, representing a
validated disease-associated transcript, is shown in Figure 2
(HKDC1). A substratification analysis performed on validation
panel I and II revealed no influence of the potential confounding
factors such as age, gender, biopsy location, andmedication on the
main findings (Supplemental Fig. S10, mRNA; Supplemental Fig.
S11, DNAm).
Combining the results of the three-layer scan and validation
showed 148-fold more MVPs in proximity to the 10 validated loci
than expected by chance, corresponding to a P-value of 9.11 3
1044 (Fisher’s exact test).
Discussion
In ulcerative colitis, the contribution of genetic variants to the
disease risk is estimated at ;16% (Anderson et al. 2011). Together
with other factors (Hampe et al. 1999; Stoll et al. 2004; Franke et al.
2008, 2010), epigenetic modifications may explain parts of the
remaining disease risk. While disease-relevant epigenetic modifi-
cations as well as their interaction with environmental factors has
been shown for other diseases (van Overveld et al. 2003; Mann
et al. 2004; Heijmans et al. 2008; Rakyan et al. 2008, 2011a;
Petronis 2010), such effects have not been shown in ulcerative
colitis. Therefore, this study aimed to create a functional epigenetic
map by combining genome-wide data of differentially methylated
regions, methylation variable positions, and transcriptome data,
reflecting potential effects of the epigenetic variations. A group of
20 monozygotic twins, discordant for UC, was selected as an entry
level to perform a three-layer genome-wide scan to target mecha-
nisms that show significant differences between healthy and dis-
eased individuals. The validity of such an approach has been re-
cently demonstrated in psoriasis and lung adenocarcinoma
(Gervin et al. 2012; Selamat et al. 2012). Obviously, such ap-
proaches cannot demonstrate the causality of epigenetic modifi-
cations for alteredmRNA levels. In addition, the features measured
by the systems employed restrict the number of detectable in-
teractions between DNAm and mRNA expression. Keeping these
limitations in mind, the presented identification of 61 cis-links
between epigenetic modifications and disease-associated tran-
scripts supports the hypothesis that pathophysiological events are
a reflection of—and potentially controlled by—epigenetic modi-
fications with consequences on transcriptional changes. The
identified cis-links show both negative and positive correlations
between DNAm and RNA expression, which is in concordance
with two recent studies applying similar approaches (Gervin et al.
2012; Selamat et al. 2012), yet the nature of positive correlations
remains unexplained by the current understanding of epigenetic
regulation. The majority of identified loci are associated with bi-
ological processes which are either directly or indirectly linked to
immune processes, which is consistent with previous findings on
functional genomics of UC (Dieckgraefe et al. 2000; Lawrance et al.
2001; Costello et al. 2005), as well as with findings on UC genetics
(Anderson et al. 2011). Interestingly, a smaller proportion of bi-
ological processes identified are distinct from bona fide immune
processes: Structural, developmental, and metabolic processes are
prominent findings. This suggests additional levels of transcrip-
tional control and is concordant with a previous study showing
that immune response-associated biological processes are not pri-
marily under genetic control in mucosal tissue (Ha¨sler et al. 2009).
Table 1. Study panels used for genome-wide assessment of differential expression and DNAm as well as for validation of initial findings
Panel type Application
Relationship of
individuals
Gender
representation
Age: Median,
range
Disease
representation
Screening panel Genome-wide screening of the transcriptome
and methylome
Discordant twins (UC, HN) 10 f 25, 18–70 10 UC
10 m 10 NC
Validation panel I Validation of the findings in the transcriptome Unrelated individuals 69 f 41, 18–76 30 UCi; 30 UCni
66 m 15 DCi; 30 DCni
30 NC
Validation panel II Validation of the findings in the methylome Unrelated individuals 25 f 41, 18–68 20 UC
(
’
panel I) 25 m 10 DC
20 NC
(f ) Female, (m) male, (UC) ulcerative colitis, (NC) normal controls, (DC) disease specificity controls; suffix: (i ) inflamed, (ni ) not inflamed.
Ha¨sler et al.
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The design used here allowed direct comparison of indi-
vidual MVPs and DMRs. While DMRs may be expected to have
greater functional relevance than MVPs, this has not yet been
formally demonstrated by any study. Consequently, both should
be part of an epigenetic map to ensure the inclusion of all po-
tentially relevant information. Based on the assessment of 23,085
CpG sites in our study, no single MVPwas found that could serve as
representative for an entire DMR. In addition, highly significant
MVPs were found in loci not showing any differential gene expres-
sion. Together with our observation that a variable number of MVPs
(in the case of our validated MVP/DMR-transcript pairs: 1–6) may
potentially influence mRNA expression, these data provide no evi-
dence that individual MVPs are of higher relevance than DMRs or
vice versa.
Previous studies have addressed the epigenetic modulation in
the context of IBD mostly from a candidate gene approach, fo-
cused on IBD-associated colorectal cancer (Moriyama et al. 2007;
Dhir et al. 2008; Edwards et al. 2009; Gonsky et al. 2011). Together
with the high tissue specificity (Rakyan et al. 2008) and the fun-
damental differences in detection, these studies are only of limited
use for comparison to our systematic genome-wide approach.
However, our results support one recent report stating that epige-
netic dysregulation of the IRF5 promoter is not associatedwith IBD
(Balasa et al. 2010). In contrast to that,many of our findings on the
mRNA level are in concordance with previously published studies
(Dieckgraefe et al. 2000; Lawrance et al. 2001; Anderson et al.
2011), potentially attributed to the lower technical and/or biological
variance in inflammation-associated mRNA patterns. Among the
replicated findings, several genes have been directly associated
with chronic intestinal inflammation; PTN (pleiotrophin) has
been shown to be functionally linked to inflammation and cancer
(Kadomatsu 2005), whileTHY1 (Thy-1 cell surface antigen)mediates
cell adhesion during inflammation (Jurisic et al. 2010). The serine
protease inhibitor SPINK4 has been shown to be differentially
expressed in chronic autoimmune intestinal inflammation (celiac
disease), likely derived from altered goblet cell activity, while no
causative genetic variant was identified (Wapenaar et al. 2007).
The ontogenetic stability of DNAm over time cannot be
assessed with our study design; however, our findings in the en-
larged validation and replication panel of unrelated patients and
controls document the relevance of our results for a more heteroge-
neous population. It is important to note that we examined the
disease specificity of our results by including inflammatory disease
controls (non-IBD-associated inflammation in the sigmoidmucosa)
in our validation panels. None of the validated candidate genes
showed DNAm variation together with altered transcript levels
when comparing diseased controls to healthy individuals. A signif-
icantly altered DNAm between inflammatory disease controls and
healthy individuals was only found for the SLC7A7 locus; however,
this was not accompanied by altered mRNA levels. These results
corroborate the potential disease specificity of the identified effects
and further support the concept of a distinct impairment ofmucosal
homeostasis in UC that is not common to intestinal inflammation
in general.
Interestingly, all of the identified disease-associated alter-
ations on mRNA, MVP, or DMR levels are novel as different to the
47 previously published UC risk loci identified by GWAS (Anderson
et al. 2011). None of the UC risk loci are considered to be meth-
ylation quantitative trait loci (Zhang et al. 2010). Furthermore, none
of the risk loci are located in a regulatory region potentially affecting
mRNA expression. In addition, the use of monozygotic twins for
the discovery phase favors identification of candidate variants that
Table 2. Validation of differential DNAm linked to disease-associated transcripts by TaqMan real-time PCR (mRNA expression in n = 135
individuals, validation panel I) and pyrosequencing (CpG methylation in n = 50 individuals, validation panel II)
Gene symbol; name
Prominent gene
ontology
terms (selected)
Cyto-genetic
band
CpG-position
relative
to transcript
CpG methylation
P-value
(observations per gene)
mRNA regulation
fold-change;
P-value
CFI; complement factor I Complement activation;
innate immune
response
4q25 Post-TSS, Y 1.51 3 1005 (2) [ 5.71;
SGB 4.45 3 1009
FLNA; Filamin A, alpha Positive regulation of I-kB
kinase/NF-kB cascade
Xq28 Post-TSS, Y 1.63 3 1002 (2) Y 2.85;
SGB 7.72 3 1006
HKDC1; hexokinase domain
containing 1
Glycolysis 10q22.1 Pre-TSS and Y 7.94 3 1006 (6) [ 2.01;
post-TSS 5.16 3 1006
IGHG1a; immunoglobulin heavy
constant gamma 1 (G1m marker)
Immune response; antigen
binding
14q32.33 Post-TSS, (–) 1.56 3 1001 (0) [ 8.25;
SGB 8.90 3 1009
MT1H; metallothionein 1H Metal ion binding; protein
binding
16q13 Post-TSS [ 1.50 3 1002 (2) Y 1.66;
3.04 3 1005
PTN; pleiotrophin Positive regulation of cell
proliferation
7q33 Post-TSS Y 2.42 3 1002 (1) Y 4.16;
2.76 3 1008
SLC7A7b; solute carrier family 7
(cationic amino acid transporter,
y+ system), member 7
Blood coagulation, leukocyte
migration
14q11.2 Post-TSS Y 5.21 3 1006 (4) (–) 1.16;
6.73 3 1001
SPINK4; serine peptidase inhibitor,
Kazal type 4
Serine-type endopeptidase
inhibitor activity
9p13.3 Post-TSS, Y 3.03 3 1006 (2) [ 13.05;
SGB 4.45 3 1009
THY1; Thy-1 cell surface antigen Positive regulation of t cell
activation
11q23.3 Post-TSS Y 2.28 3 1003 (2) [ 2.99;
4.75 3 1007
TK1; thymidine kinase 1, soluble DNA replication 17q23.2– Pre-TSS [3.08 3 1003 (2) [ 1.32;
q25.3 2.30 3 1002
(TSS) Transcription start site; (SGB) spanning to gene body; in case of multiple CpGs, all relative positions are described. ([) Up-regulation; (Y) down-
regulation; (–) no regulation as measured in the validation panel. P-values presented were corrected for multiple testing using the Benjamini-Hochberg
correction. In case of multiple observations, the lowest P-values were presented.
aNegative control candidate for differential expression without epigenetic modification.
bNegative control candidate for epigenetic modification without differential mRNA expression.
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are independent of genetic effects. This also reflects fundamental
differences between GWAS and EWAS approaches, as outlined re-
cently (Rakyan et al. 2011b): EWAS, especially when conducted in
monozygotic discordant twins and linked to transcriptome anal-
ysis, represents a powerful complementary tool to detect variations
which cannot be captured by a GWAS.
Finally, the potential clinical relevance of our findings is
supported by the high frequencies at which these effects occur: In
93% of all individuals, decreased methylation at these candidate
loci is reflected by up-regulation of the corresponding transcript
(or vice versa) when comparing UC patients to healthy controls.
Moreover, we observed ;150-fold more MVPs in the proximity to
the validated candidate loci than expected by chance. This also
indicates a high robustness of cis-links between epigenetic modi-
fications and regulation of disease-associated transcripts.
In conclusion, our results indicate that changes in DNAmand
their consequences on the transcriptome may represent disease
mechanisms for UC, independent of genetic variation. The use of
primary tissue frommonozygotic disease-discordant twins followed
by the validation of the findings in a larger and independent panel
of UC patients supports the potential
disease relevance of our observations. In
addition, the disease specificity of the
observed events is strengthened by our
study design, which controlled for con-
founding non-disease-associated varia-
tion, e.g., due to inflammation. While our
data are suggestive of a link between
DNAm and its effects on mRNA expres-
sion, it remains a challenge to formally
establish causality. Nevertheless, the in-
tegrated three-layer functional map re-
ported here will contribute toward a bet-
ter understanding of IBD pathophysiology,
further closing the gap between un-
explained disease susceptibility and dis-
ease manifestation.
Methods
Patient recruitment and patient
characteristics
The twenty monozygotic twins, discor-
dant for ulcerative colitis (screening panel;
median age: 25, range 18–70) recruited for
this study were tested for mono/dizygosity
as previously published (Barbaro and
Cormaci 2004; vonWurmb-Schwark et al.
2005). The panel for real-time PCR vali-
dation of transcript levels consisted of
135 unrelated individuals (validation
panel I; n = 30 ulcerative colitis, inflamed;
n = 30 ulcerative colitis, noninflamed; n =
30 healthy individuals; n = 15 disease
controls, inflamed; n = 30 disease con-
trols, noninflamed; median age: 41, age
range 18–76), a subgroup of which was
used for pyrosequencing validation of
methylation levels (validation panel II;
n = 20 ulcerative colitis, inflamed; n = 20
healthy individuals, n = 10 disease con-
trols, inflamed; median age: 41, age
range 18–68). Healthy individuals included in the study were
undergoing colonic cancer surveillance with no previous un-
specific changes in stool habits, where endoscopic and histological
examination yielded no significant pathological findings. Ulcera-
tive colitis patients were selected to display an endoscopically ac-
tive disease in the sigmoid colon at the time of sampling. In-
flammationwas assessedmacroscopically during colonoscopy and
categorized into (1) no signs of inflammation, (2) low inflam-
mation, and (3) moderate/high inflammation, while only tissue
with no ormoderate/high inflammationwas included in the study
(see Supplemental Table S3). More than 2000 patients were
screened to recruit the study population. Disease-specificity con-
trols included individuals with infectious diarrhea, other forms of
gastrointestinal inflammation or irritable bowel syndrome. The
study setup was approved by the Bioethical Committee of the
University of Kiel, where the patients were recruited. All patients
gave written informed consent before data and biomaterials were
collected. Patient characteristics are summarized in Table 1; amore
detailed description of patient characteristics is presented in Sup-
plemental Table S3 (A: screening panel; B: validation panel I; C:
validation panel II).
Figure 2. Validation of DNAm and gene expression in selected candidate transcripts; example:
HKDC1. (A) Relative position of CpGs (arrows up, continuously numbered 1–8) and real-time PCR probe
(dark gray). (B) Quantitative results of the validation: (1) methylation (via pyrosequencing, CpGs
continuously numbered 1–8 in concordance with Fig. 2A) in n = 50 individuals (validation panel II); the
order of assays displayed corresponds to the order in Figure 2A; (2)mRNA (via real-time PCR, right) in n =
135 individuals (validation panel I). (C ) Correlation between mRNA expression (x-axis) and relative
methylation (y-axis) in HKDC1 for a selected CpG; the dotted line represents the correlation trend
(Spearman-r r =7.43). Significant differences between UC patients and normal controls are indicated
by asterisks ([*] P # 5 3 103; [**] P # 5 3 104; [***] P # 5 3 106).
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Biopsy processing and sample preparation
All biopsies used in this study are primary tissue from the intestinal
mucosa. Biopsies were taken endoscopically from a defined area of
the colon and immediately snap-frozen in liquid nitrogen. Total
RNA was extracted and processed as previously described (Mah
et al. 2004) and quality controlled using an Agilent Bioanalyzer
according to themanufacturer’s guidelines. DNAwas extracted from
biopsies using the QIAamp Tissue DNA preparation kit (Qiagen).
Expression profiling (mRNA, layer I)
Total RNA was prepared and hybridized to an Affymetrix UG 133
Plus 2.0 according to the manufacturer’s protocol. Data was nor-
malized using GCRMA (R, Bioconductor), and signals that were not
present in at least 80% of the samples (cutoff: detection P-value #
0.05) were excluded from further analysis. The experimental and
analytical part of the microarray analysis was performed following
the MIAME standards, including the data submission to Gene
Expression Omnibus. (GEO, URL: http://www.ncbi.nlm.nih.gov/
geo, series: GSE22619; samples: GSM560961–GSM560976). Dif-
ferentially expressed genes were determined using the Mann-
Whitney U-test, multiple testing correction was performed using
the Benjamini-Hochbergmethod (Benjamini andHochberg 1995),
and a false discovery rate for the signed fold changes (which were
based on the ratios of the medians of each group compared) was
estimated based on a Westfall and Young permutation, using K =
5000 permutations (Westfall and Young 1993). Criteria for tran-
scripts to be categorized as differentially expressed were set to: (1)
corrected P-value # 0.05, and (2) FDR # 5%.
Analysis of methylation variable positions (MVPs, layer II)
DNA was prepared and analyzed using HumanMethylation27
BeadChips (iScan system, Illumina) as previously described (Van
der Auwera et al. 2010), while the data set was subject to intra-array
and inter-array normalization as published earlier (Teschendorff
et al. 2010). Differences between ulcerative colitis patients, dis-
eased controls, and healthy individuals were determined using the
Mann-Whitney U-test, while P-values were corrected according to
Benjamini and Hochberg (Benjamini and Hochberg 1995). MVPs
with a corrected P-value # 0.05 were considered significantly dif-
ferentially methylated.
Analysis of differentially methylated regions (DMRs, layer III)
DNA was prepared and hybridized to a custom tiling array
(Nimblegen, custom 385k array) as previously described (Rakyan
et al. 2008). The array was designed to cover known autoimmune/
inflammatory-linked loci as well as specific genes with immune-
regulatory function and encompassed all known promoters and
CpG islands (both promoter- and non-promoter-CpG islands).
Data was normalized applying the inter-quantile normalization
using Spotfire for functional genomics (TIBCO). Differences be-
tween ulcerative colitis patients, diseased controls, and healthy
individuals were determined using the Mann-Whitney U-test,
while P-values were corrected according to Benjamini and Hochberg
(Benjamini and Hochberg 1995). DMRs with a corrected P-value #
0.05 were considered significantly differentially methylated.
Integration of three layers of genome-wide scans,
candidate selection
To identify disease associated transcripts under potential epige-
netic control, differentially expressed transcripts from layer I were
selected (corrected P # 0.05, FDR # 5%, regulated between
healthy and diseased individuals). The genomic transcript lo-
cations were used to generate interaction windows of 50 kb
upstream of and downstream from the transcription start site
(TSS). These windows were examined to see whether they con-
tain either a DMR (layer II, corrected P # 0.05, between healthy
and diseased individuals) or a MVP (layer III, corrected P# 0.05,
between healthy and diseased individuals). Transcripts signifi-
cantly regulated between healthy and diseased individuals, with
a significantly regulated DMR or MVP within the 50-kb win-
dow of the TSS, were considered candidates for disease-associ-
ated transcripts under potential epigenetic control. Correlating
quantitative expression values with DMRs andMVPs within this
window was carried out using the Spearman-r correlation. Dif-
ferences between sets of correlation (all genes, disease-associated
transcripts, and validated transcripts) were assessed using the
Mann-Whitney U-test.
Validation of differential mRNA expression via real-time PCR
Real-time PCR (TaqMan) was performed according to the man-
ufacturer’s guidelines (Applied Biosystems) using a 7900HT
Real-Time PCR System. Expression levels were calculated rela-
tive to beta-actin using the standard-curve method (Livak and
Schmittgen 2001). Differences between ulcerative colitis pa-
tients, diseased controls, and healthy individuals were de-
termined using the Mann-Whitney U-test, while P-values were
corrected according to Benjamini and Hochberg (Benjamini
and Hochberg 1995).
Validation of differential DNAm via pyrosequencing
Validation of initial findings was performed via bisulfite conver-
sion followed by pyrosequencing (Roche, 454) as previously de-
scribed (Bollati et al. 2007). Differences between ulcerative colitis
patients, diseased controls, and healthy individuals were de-
termined using the Mann-Whitney U-test, while P-values were
corrected according to Benjamini and Hochberg (Benjamini and
Hochberg 1995).
Gene ontology analysis
Gene ontology analysis was performed as previously published
(Tavazoie et al. 1999). Biological processes associated with the
transcripts and candidate genes were retrieved from the Gene
Ontology Consortium (www.geneontology.org).
Determination of effect frequencies
Frequencies of validated effects were determined by assessing the
number of occurrences, where an effect was following the varia-
tion pattern observed when comparing the medians of ulcerative
colitis versus healthy individual signals. An effect was considered
significant when both differential DNAm and differential mRNA
expression showed Benjamini-Hochberg-corrected P-values# 0.05
in the validation experiment.
Data access
Genome-wide data sets (three layers) of all individuals included
in the study have been submitted to the NCBI Gene Expression
Omnibus (GEO) (http://www.ncbi.nlm.nih.gov/geo/) under series
accession numbers GSE22619 (samples: GSM560961–GSM560976)
and GSE 27899 (samples GSM688887–GSM688926).
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